Bifunctional Dalteparin/Enoxaparin coated nanosilver formulation to prevent bloodstream infections during hemodialysis

Carbohydr Polym. 2022 Sep 1:291:119546. doi: 10.1016/j.carbpol.2022.119546. Epub 2022 Apr 29.

Abstract

Catheter-related bloodstream infections (CRBSI) are the major concern of patients undergoing hemodialysis. The current study formulates bifunctional low molecular weight heparin (LMWH) coated nanosilver as an effective anticoagulant and antimicrobial/anti-biofilm agent. Nanosilver formulations were prepared using a microwave-assisted green synthesis approach and stabilized with pharmaceutically approved LMWH such as dalteparin (DL) and enoxaparin (EX) along with unfractionated heparin (HP) as a control. The obtained heparinized (HP/DL/EX) nanosilver was monodisperse, and the size ranged between 15 and 25 nm. DL/EX predominantly stabilized the nanosilver by primarily engaging their negatively charged sulfate groups. The obtained DL/EX coated nanosilver are hemocompatible, showed two times increase in their anticoagulation activity, and are highly potent in inhibiting/eradicating both mono- and polymicrobial biofilms. Henceforth, the observed biocompatible and enhanced bifunctional characteristics of DL/EX coated nanosilver can be used to replace the systemic antibiotics and can be an alternative catheter lock solution to prevent CRBSI in hemodialysis therapy.

Keywords: Anticoagulant; CVC related infections; Dalteparin; Enoxaparin; Low molecular weight heparin; Microbial biofilms; Nanosilver.

MeSH terms

  • Anticoagulants / pharmacology
  • Anticoagulants / therapeutic use
  • Dalteparin*
  • Enoxaparin / pharmacology
  • Heparin
  • Heparin, Low-Molecular-Weight
  • Humans
  • Renal Dialysis / adverse effects
  • Sepsis*

Substances

  • Anticoagulants
  • Enoxaparin
  • Heparin, Low-Molecular-Weight
  • Heparin
  • Dalteparin